Nachrichten zur Zymeworks Inc. Aktie

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

…

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms…

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

…

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript

…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

ZYMEWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymeworks Inc. on Behalf of Zymeworks Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zymeworks Inc. (ZYME)

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript

…

Zymeworks files to sell 5.09M shares for its holders

…

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Additional Leadership Appointments

VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks to join Nasdaq Biotechnology Index

…

Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript

…

Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks To Host Third Quarter 2023 Results Conference Call

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces New Director Nominee

VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do…

Zymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results

VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks To Host Second Quarter 2023 Results Conference Call

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Announces Participation in Upcoming Investor Conference

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Form 8-K Zymeworks Inc. For: Jun 26

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Appoints New Director

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Form 8-K Zymeworks Inc. For: Jun 12

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Zymeworks Inc. For: Jun 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Zymeworks COO to step down

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYME

Zymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYME...…

Form 8-K Zymeworks Inc. For: May 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer

VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing…

Form 8-K Zymeworks Inc. For: May 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do…

Zymeworks GAAP EPS of -$0.37 beats by $0.12, revenue of $35.58M beats by $16.06M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…